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Abstract The thiazide-sensitive NaCl cotransporter (NCC)
plays key roles in renal electrolyte transport and blood
pressure maintenance. Regulation of this cotransporter has
received increased attention recently, prompted by the
discovery that mutations in the with-no-lysine (WNK)
kinases are the molecular explanation for pseudohypoal-
dosteronism type II (PHAII). Studies suggest that WNK4
regulates NCC via two distinct pathways, depending on its
state of activation. Furthermore, an intact STE20-related
proline–alanine-rich kinase (SPAK)/oxidative stress re-
sponse 1 kinase (OSR1) pathway was found to be necessary
for a WNK4 PHAII mutation to increase NCC phosphor-
ylation and blood pressure in mice. The mouse protein 25α
is a novel regulator of the SPAK/OSR1 kinase family,
which greatly increases their activity. The phosphorylation
status of NCC and the WNK is regulated by the serum- and
glucocorticoid-inducible kinase 1, suggesting novel mech-
anisms whereby aldosterone modulates NCC activity.
Dephosphorylation of NCC by protein phosphatase 4
strongly influences the activity of the cotransporter,
confirming an important role for NCC phosphorylation.
Finally, γ-adducin increases NCC activity. This stimulatory
effect is dependent on the phosphorylation status of the
cotransporter. γ-Adducin only binds the dephosphorylated
cotransporter, suggesting that phosphorylation of NCC
causes the dissociation of γ-adducin. Since γ-adducin is
not a kinase, it is tempting to speculate that the protein
exerts its function by acting as a scaffold between the
dephosphorylated cotransporter and the regulatory kinase.
As more molecular regulators of NCC are identified, the
system-controlling NCC activity is becoming increasingly
complex. This intricacy confers an ability to integrate a
variety of stimuli, thereby regulating NCC transport activity
and ultimately blood pressure.
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Introduction
Studies of electrolyte transport within the renal distal
convoluted tubule (DCT) led to the identification of a
thiazide-sensitive component that permits vectorial NaCl
cotransport. The thiazide-sensitive NaCl cotransporter
(NCC) was subsequently cloned from the urinary bladder
of the winter flounder, Pseudopleuronectes americanus
[16]. Gitelman’s syndrome is an autosomal recessive salt-
losing disorder characterized by hypokalemic metabolic
alkalosis, hypomagnesemia, and hypocalciuria [20, 43].
Genetic mapping studies in patients with Gitelman’s
syndrome revealed that the defect was the result of
mutations in the SLC12A3 gene, which encodes NCC
[43]. Later studies led to the discovery of an intricate kinase
network that regulates the function of NCC by modifying
the phosphorylation level, trafficking, and lysosomal sort-
ing of the protein. These discoveries were initially
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an autosomal dominant disorder associated with hyperten-
sion, namely pseudohypoaldosteronism type II (PHAII;
also known as Gordon syndrome) [48].
Subsequent studies have shown that NCC plays a critical
role in renal NaCl transport and blood pressure mainte-
nance. Thiazides, the pharmacological inhibitor of NCC,
remain one of the most effective and prescribed drugs in the
treatment of hypertension. As such, knowledge regarding
the regulation of NCC is a critical step in understanding the
development and underlying pathogenesis of hypertension.
This article aims to review the discovery of novel factors
that regulate the cotransporter. These proteins appear to act
as members of a cellular network that relay and integrate
signals to alter NCC function and, consequently, blood
pressure.
Mechanisms of NCC regulation
The majority of studies on NCC function have been
conducted in the Xenopus laevis oocyte expression system.
Injection of cRNA-encoding NCC into oocytes generates a
stable and reproducible thiazide-sensitive uptake of
22Na
+.
The results are less consistent when mammalian cell
systems are employed. Several groups have reported
thiazide-sensitive
22Na
+ uptake in mammalian cell lines
expressing NCC, while others have failed to do so. For this
reason, many still utilize the oocyte expression system to
study NCC activity. The results obtained in the oocyte as
well as mammalian cell systems are often in line with those
obtained in vivo and thus suggest that these cellular models
can be used to study NCC function. As will be evident in
this review, the network of auxiliary proteins regulating
NCC is expanding rapidly. Whether or not all members of
this regulatory network are present in these cell models, it is
uncertain and must be taken into account when analyzing
the responses of the system.
NCC can be regulated in a variety of ways including:
changes in expression, trafficking, and phosphorylation.
These processes all ultimately affect the net flow of NaCl
across the DCT. Transcriptional regulation leading to changes
in NCC abundance occurs after hormonal stimuli and is often
thought of as a chronic adaptation to various alterations in the
total body NaCl balance. More rapid regulatory processes
include changes in trafficking and phosphorylation of the
cotransporter.TheaminoN-terminaldomainofNCCcontains
several phosphorylation sites (including Thr
46,T h r
55,T h r
60,
Ser
73, and Ser
91 in human NCC), quite a few of which are
conserved among members of the SLC12 family [8, 18, 19,
34, 37]( F i g .1). Although the understanding of the
individual contributions of each phosphorylation site is
incomplete, several observations have suggested that phos-
phorylation of these residues, especially that of Thr
60,i s
critically important for the activation of NCC. When several
of the N-terminal phosphorylation sites in NCC [9, 34]o r
Thr
60 alone [21] is converted to constitutively inactive sites
by substitutions to alanine, the transport activity of NCC is
markedly decreased in the X. laevis expression system.
Interestingly, the process seems to occur without altering
membrane localization. This observation infers that phos-
phorylation at these sites is important for intrinsic activity of
the cotransporter [21, 34]. Furthermore, while increasing the
phosphorylation status of the cotransporter by incubating
NCC-expressing oocytes in hypotonic, low Cl
−-containing
media increases transport activity without changing mem-
brane abundance of the protein [34]. Studies in human
embryonic kidney cells further demonstrate that mutation of
Thr
60 specifically prevents the phosphorylation of several of
the other N-terminal residues and coincides with a reduction
in thiazide-sensitive Na
+ transport. This likely explains why
individuals with a mutation in the Thr
60 phosphorylation site
(converted to methionine) present with Gitelman’ss y n d r o m e
[29]. Moreover, it highlights the fact that intact NCC
phosphorylation sites are necessary for renal NaCl reabsorp-
tion and the maintenance of blood pressure. Interestingly,
while phosphorylation of the N-terminal residues in NCC
seems dissociated from trafficking in the oocyte, studies
suggest that the phosphorylated cotransporter is found only
in the apical membrane of the DCT cell in rat [35]. These
observations could indicate that phosphorylation of NCC at
the N terminus only occurs when the cotransporter is
anchored in the plasma membrane. Several novel phosphor-
ylation sites including Ser
124 (rat, equivalent to Ser
126 in
human NCC) and Ser
811 in NCC have recently been
identified; however at the present time, no function has been
assigned to these residues [12, 23]( F i g .1).
In addition to phosphorylation, trafficking of NCC from
subapical vesicles to the plasma membrane may also be an
important factor in regulating NaCl cotransport in the DCT.
Although several of the N-terminal phosphorylation sites
appear to regulate transport independently of changes in the
subcellular localization of NCC, it remains unclear whether
the trafficking process is dependent on phosphorylation of
other sites within the cotransporter. Rapid alterations in
membrane expression of NCC are seen after angiotensin II
infusion in rats, which provokes movement of the cotrans-
porter into the apical plasma membrane from subapical
vesicles [41].
The WNK kinase family
The WNK family of serine–threonine kinases has a
characteristic displacement of a catalytic lysine residue
necessary for ATP binding, hence the name with-no-k
768 Pflugers Arch - Eur J Physiol (2011) 462:767–777(lysine) [46, 50]. The role of the WNK family in the
maintenance of ambient blood pressure has been firmly
established. PHAII patients have defects in either the
WNK1 or WNK4 genes and suffer from increased renal
reabsorption of NaCl and consequently elevated arterial
pressure [24, 48]. Specifically, autosomal dominant muta-
tions in the WNK4 gene or intronic deletions of the WNK1
gene (that massively increase its transcript) are responsible
for PHAII [48].
Thiazide diuretics are known to normalize blood
pressure and correct electrolyte abnormalities when admin-
istered to PHAII patients [10], implicating a prominent role
for NCC in this disease. WNK4 has subsequently been
found to inhibit NCC transport by reducing plasma
membrane abundance of the cotransporter in the oocyte
expression system [49, 53]. Recent studies have shown that
WNK4 inhibits NCC activity by diverting the cotransporter
to the lysosomal compartment during forward trafficking.
This likely occurs via a sortilin-dependent mechanism [44,
59]( F i g .2a). The inhibitory effect of WNK4 occurs
independently of NCC phosphorylation of Thr
58 (equiva-
lent to Thr
60 in humans), which is important for NCC
activity [21, 22]. Loss-of-function mutations in WNK4
have been the suggested molecular mechanism of PHAII.
Here, mutations in WNK4 increase NCC abundance by
reverting the inhibitory effect on lysosomal shuttling of
NCC (Fig. 2b). One PHAII-causing mutation in WNK4
(Q562E) reduced the inhibitory effect of WNK4 on NCC
activity and trafficking [49, 53]. However, in the same
study, several other PHAII-causing mutations of WNK4
failed to inhibit the activity of the cotransporter [53].
Contrasting these observations is the finding that WNK4
stimulates N-terminal phosphorylation and hence activity of
NCC in the same cellular systems. This occurs via WNK4-
dependent activation of the STE20 family of serine/threonine
kinases, namely the STE20-related proline–alanine-rich ki-
nase (SPAK) and oxidative stress response 1 kinase (OSR1)
[47]. Additionally, angiotensin II increases NCC activity in
the Xenopus oocyte system, but only in the presence of
WNK4. This stimulatory effect of angiotensin II on NCC is
dependent on SPAK activation and coincides with increased
phosphorylation of the cotransporter [40]( F i g .3a). More-
over, this study could not detect any additional stimulatory
effect of angiotensin II on NCC activity when a PHAII
mutant of WNK4 was expressed, suggesting that the mutated
WNK4 was already in an activated state [40]. The positive
effect of WNK4 on NCC activity may be due to an elevation
of intracellular Ca
2+, which is released after angiotensin II
application. San-Cristobal et al., the authors of this study,
highlighted the fact that PHAII mutations in WNK4 are
situated in a negatively charged domain of the WNK4
protein. This part of WNK4 bears some similarity to a Ca
2+-
Plasma membrane
Thr46
Thr55 Thr60 Ser73
Ser91
Ser126
SPAK/OSR1 binding 
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Fig. 1 Schematic diagram of human NCC, depicting the various
phosphorylation sites within the cotransporter. Please note that Ser
126
has not been described in human NCC, but has been identified as Ser
124
in rat NCC. In addition, binding sites for the SPAK/OSR1 kinases as
well as the γ-adducin-binding region are indicated in the figure
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mutations in this domain may switch WNK4 into an active
state, thereby stimulating the SPAK and OSR1 kinases to
phosphorylate NCC and subsequently causing the PHAII
phenotype (Fig. 3b).
Studies directed at understanding the effect of WNK4 on
NCC function in these cellular systems seem contradictory.
However, the studies can be reconciled if both the inhibitory
and stimulatory pathways coexist within the cell. Thus,
WNK4 may act as a potent stimulator or inhibitor of NCC,
depending on its state of activation. Without adequate
stimulation, WNK4 is likely to be inhibitory, shuttling NCC
into lysosomes and reducing transport activity by doing so.
However, in the presence of stimuli (such as angiotensin II),
WNK4 will increase NCC transport via activation of the
SPAK/OSR1 pathway. Although not yet described, there may
also be factors that switch WNK4 in the opposite direction,
thereby favoring the inhibitory pathway. A better understand-
ing of the factors that are involved in changing WNK4’ss t a t e
of activation will be important to our understanding of NCC
biology. The biphasic effects of WNK4 may also help explain
why in vivo experiments using mice with a genetically
modified WNK4 pathway can yield conflicting results.
Hypomorphic mice with a targeted deletion of exon 7 in the
Wnk4 gene have a partially functional WNK4. The hypo-
morphic strain presented with a lower blood pressure and
increased NaCl excretion during dietary salt restriction, as
well as reduced NCC phosphorylation [33]. These observa-
tions infer that WNK4 is predominantly stimulatory under
basal conditions in vivo. This also raises the question whether
PHAII occurs as the result of loss-of-function or gain-of-
function mutations in WNK4. In transgenic knock-in mice
with a PHAII-mutated Wnk4 gene (D561A), there is increased
phosphorylation of NCC, suggesting that the SPAK/OSR1
pathway is activated [54]. Recent data from Chiga et al.,
utilizing triple knock-in mice strains with a PHAII-mutated
WNK4
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Fig. 2 The “inhibitory” pathway of WNK4. a WNK4 diverts NCC to
the lysosomal compartment during forward trafficking of the
cotransporter to the plasma membrane. WNK3 interacts with
WNK4, potentially preventing the WNK4-induced shuttling of NCC
to the lysosome. WNK1 also inhibits WNK4 by interacting with the
protein. In addition, WNK1-KS acts by inhibiting WNK1, thereby
releasing WNK1’s inhibition on WNK4, thus increasing the inhibitory
effect of WNK4 upon NCC. b Potential mechanism by which loss-of-
function mutations in WNK4 leads to PHAII. Loss-of-function
mutations in WNK4 reduce the ability of the kinase to shuttle NCC
to the lysosomes during forward trafficking, thereby increasing the
abundance of the cotransporter in the apical plasma membrane. c An
increase in the WNK1 protein occurs due to intronic deletion in its
gene. Increased expression of WNK1 in this “inhibitory” pathway
would lead to a marked inhibition of WNK4, thus increasing NCC
membrane abundance and thereby causing PHAII
770 Pflugers Arch - Eur J Physiol (2011) 462:767–777WNK4 (D561A) and non-activatable SPAK and OSR1 (one
allele) kinases, have shed light on this issue [5]. In contrast to
the single knock-in WNK4 mutant mice strain, which have a
PHAII-like phenotype and increased phosphorylation of
NCC, triple knock-in mice fail to display a hypertensive
phenotype and demonstrate reduced phosphorylation of NCC
[5]. These data suggest that the WNK4-stimulated SPAK/
OSR1 pathway is primarily responsible for the PHAII
phenotype, at least for this particular WNK4 mutant.
However, this does not exclude an important role for the
inhibitory actions of WNK4 in the lysosomal sorting of NCC.
Transgenic mice overexpressing another PHAII WNK4
mutant (Q562E) show a hypertensive phenotype similar to
patients with PHAII. These mice display marked hyperplasia
of the DCT and elevated expression of NCC. However, mice
overexpressing wild-type WNK4 show the opposite pheno-
type, with lower blood pressure, atrophy of the DCT, and
reduced NCC expression [27]. This suggests that a surplus of
wild-type WNK4 in the intact animal can lead to an inhibition
of NCC. The inhibitory pathway is likely to be operating
during conditions when WNK4 is not in its activated form, as
exemplified by mice engineered to have extra wild-type
WNK4 alleles and in the study discussed below.
A recent study by Mu et al. showed that the WNK4
pathway plays an important role in salt-sensitive hyperten-
sion [31]. Activation of the adrenergic pathway in mice
placed on a high-NaCl diet causes hypertension, increased
expression of NCC, in addition to a reduced renal WNK4
content. These effects were not observed in β2-adrenergic
receptor knockout mice. Interestingly, the authors found
that the glucocorticoid receptor was necessary for the
observed decrease in WNK4 abundance. This was elegantly
demonstrated by utilizing mice with a targeted deletion of
the glucocorticoid receptor in the distal nephron. This strain
did not decrease WNK4 abundance or increase blood
pressure when placed on high-NaCl diet and infused with
β-adrenergic agonists [31]. The current study shows a clear
role for WNK4 and NCC in salt-sensitive hypertension.
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Fig. 3 The“stimulatory”pathway ofWNK4. a Activation of WNK4 by
angiotensin II potentially occurring via elevations in intracellular Ca
2+.
In this state, WNK4 stimulates the SPAK/OSR1 pathway. Cl
−-depletion
and K
+-depletion activates WNK1, thereby activating the SPAK and
OSR1 kinases. In both cases, activation of the STE20 kinases leads to
increased phosphorylation level of NCC. The augmented phosphoryla-
tion level of NCC increases cotransport activity. b Potential mechanism
whereby gain-of-function mutations in WNK4 causes PHAII. Increased
activity of WNK4 due to PHAII mutations increases its stimulatory
effect on the SPAK/OSR1 pathway. This enhances phosphorylation of
NCC and thereby increases NaCl transport, leading to PHAII. c An
increase in the expression of WNK1 stimulates the activation of the
SPAK/OSR1 kinases, which subsequently increases the phosphorylation
level of NCC
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have an inhibitory effect on NCC in vivo during certain
conditions. Although the amount of phosphorylated NCC is
increased in this study, it is not clear whether this is a
reflection of increased NCC expression or an actual
increase in the phosphorylation level of the cotransporter.
Therefore, it remains to be determined to what extent the
SPAK/OSR1 pathway is activated in these experiments and
what signaling cascade is involved in stimulating it. As
discussed below, several members in the regulatory
complex surrounding NCC act by modifying WNK4
function. Depending on WNK4’s state of activation, the
role of the kinase may be dramatically different. Further
research directed at dissecting out when each pathway
predominates would aid tremendously in understanding
how other regulatory proteins influence NCC function by
modifying WNK4.
In the Xenopus oocyte system, WNK1 imposes an
inhibitory effect on WNK4, abrogating its ability to shuttle
NCC into lysosomes (Fig. 2a). This mechanism potentially
explains why increased WNK1 protein expression results in
the same PHAII phenotype caused by mutations in WNK4
[53]( F i g .2c). The inhibitory effect of WNK1 on WNK4
might stem from interaction between the two kinases,
leading to phosphorylation of WNK4 [39, 55]. However,
WNK1 also activates the SPAK/OSR1 pathway during
hypotonic Cl
−-depleted or K
+-depleted conditions [32, 37,
47]( F i g .3a). Thus, overexpression of WNK1 in PHAII may
increase the phosphorylation level and hence transport
activity of NCC by activation of SPAK and OSR1
(Fig. 3c). The exact underlying molecular mechanism
mediating PHAII via WNK1 overexpression is unclear. If
WNK4 functions as a stimulator of NCC transport during
basal conditions in the intact animal [33], it seems to reason
that WNK1 overexpression in PHAII patients must result
from activation of the SPAK/OSR1 pathway. Further data are
necessary to confirm this, especially studies that dissect out
all possible mechanisms by which WNK1 can inhibit
WNK4. Regardless of the mechanism, it is clear from these
data that WNK1 is a potent regulator of renal electrolyte
transport and blood pressure, as is WNK4. This is consistent
with the observation that heterozygous mice with genetic
ablation of the Wnk1 gene have reduced blood pressure [58].
However, part of this response is likely caused by alterations
in vascular tone, due to reduced phosphorylation of SPAK
and NKCC1 in the arteries of this strain [1].
Although the role of WNK3 remains to be fully clarified,
it is known that this kinase markedly stimulates the activity
of NCC in the X. laevis expression system [38]. This
stimulatory effect occurs by phosphorylating and conse-
quently inhibiting WNK4, a mechanism that likely prevents
shuttling of the cotransporter to the lysosomes [55]. The
stimulatory effect of WNK3 on NCC coincides with
increased plasma membrane expression of the cotrans-
porter. This process occurs independently of Thr
60 phos-
phorylation on NCC [21].
The aldosterone-regulated splice variant of WNK1, termed
kidney specific WNK1 (WNK1-KS), inhibits the function of
full-length WNK1, thereby reducing NCC activity [55]. This
is in line with the observation that mice lacking WNK1-KS
has increased mean arterial pressure as well as increased
expression and phosphorylation of NCC [25].
The STE20 family of serine/threonine kinases
WNK-stimulated phosphorylation of NCC is largely medi-
ated by the STE20 family of serine/threonine kinases,
specifically the members SPAK and OSR1. Both kinases
directly phosphorylate NCC on Thr
46, Thr
55, and Thr
60
[37]. The kinases require a docking interaction between
their conserved C-terminal domains and the SPAK/OSR1
binding motif (RFx[V/I]) in NCC to enable these phos-
phorylation events [37, 47] (Fig. 1). Moreover, phosphor-
ylation of Ser
71 is altered in SPAK-deficient mice (Ser
73 in
humans), suggesting that the kinase is required for
phosphorylation of this site [56]. Recently, it was demon-
strated that when the SPAK/OSR1 pathway is enhanced,
phosphorylation of Ser
73 is also increased in vitro [13].
Both WNK1 and WNK4 interact with SPAK and OSR1,
and only the catalytically active WNKs are able to
phosphorylate the SPAK/OSR1 kinases [47]. The WNKs
contain SPAK/OSR1-binding motifs that allow them to
interact with the STE20 kinases [15, 30, 47]. Further,
phosphorylation of STE20 substrates by the WNKs
increases both SPAK and OSR1 activity. Mutating one of
these phosphorylation sites, namely the T-loop threonine
residues in SPAK (Thr
233) or OSR1 (Thr
185), prevents
activation of the kinases [5, 47].
Mutation of Thr
185 in OSR1 to alanine causes embryonic
lethality of the knock-in mice, while strains with Thr
233 in
SPAK are born at the expected Mendelian ratio [36]. These
latter mice are hypotensive, a feature that is normalized by
supplementing the animals with dietary NaCl. As expected,
the animals have a marked reduction in NCC phosphoryla-
tion. In addition, a decrease in NCC abundance was also
observed, without a concomitant reduction in mRNA,
suggesting that the stability of the protein was somehow
affected by inactive SPAK kinases [36]. Mice with a genetic
deletion of the Spak gene show a similar phenotype as those
with an inactivatable kinase, but several differences exist. For
instance, these mice develop electrolyte abnormalities consis-
tent with a Gitelman-like phenotype. Moreover, a reduction in
endothelial NKCC1 phosphorylation is present, suggesting
that impaired aortic contractility may contribute to the
hypotensive phenotype [56].
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MO25α was recently discovered to be a master regulator of
several members of the STE20 kinase family, including
SPAK and OSR1 [13]. The protein is classically described
as a scaffold that regulates the LKB1 tumor suppressor
kinase complex. Conserved MO25α-binding sites were
identified within both the SPAK and OSR1 kinases. Co-
expression of MO25α with these kinases stimulated their
activity as much as 70–100-fold. This remarkable increase
in activation only occurs when the kinases are activated (i.
e., by changing the T-loop threonine residues in SPAK
(Thr
233) and OSR1 (Thr
185) to Glutamic acid residues). The
WNK family phosphorylates these T-loops threonines and
similar increases in the activity of wild-type OSR1 were
observed when WNK1 was present. Knockdown of the
MO25α protein did not affect the phosphorylation of
SPAK/OSR1 by WNK1, suggesting that the binding of
MO25α does not facilitate this process. As expected,
phosphorylation of the N-terminal residues on NCC is
markedly enhanced after this MO25α-dependent increase
in activation of the SPAK/OSR1 kinases [13]. Many
laboratories have reported difficulty establishing mammali-
an cell lines expressing NCC that display thiazide-sensitive
transport. Perhaps co-expression of MO25α may help
alleviate this problem by assuring maximal activation of
NCC.
The serum- and glucocorticoid-inducible kinase 1
Serum- and glucocorticoid-inducible kinase 1 (SGK1) is
involved in controlling several renal electrolyte transport
processes. Part of the “early response” to aldosterone on
renal electrolyte transport has been ascribed to translational
upregulation of this kinase. The effect of SGK1 on
epithelial transport has been well described for the
epithelial Na
+ channel (ENaC), where the kinase markedly
stimulates channel activity [3]. This stimulatory effect on
ENaC is achieved by phosphorylating the ubiquitin ligase
Nedd4-2, preventing it from ubiquitinating ENaC and
consequently marking it for degradation [28]. Genetic
ablation of Sgk1 in mice results in salt wasting, which is
only obvious when the mice are maintained on low dietary
NaCl. In addition to a defect in ENaC cleavage, these mice
present with a reduced expression of NCC [11]. When
normal mice are placed on a low-NaCl diet, NCC
abundance as well as phosphorylation of Thr
53, Thr
58, and
Ser
71 is increased (equivalent to Thr
55, Thr
60, and Ser
73 in
humans). Interestingly, this response is attenuated in mice
with a targeted deletion of the Sgk1 gene, suggesting that
SGK1 somehow affects NCC phosphorylation [45]. Wheth-
er the reduced expression of NCC is dependent upon a
reduction in phosphorylation of the cotransporter, as
reported by others, remains to be seen [5, 36, 56]. In the
X. laevis system, WNK4 inhibits the activity of NCC under
basal conditions by diverting the cotransporter to the
lysosome. Here, SGK1 functions as an inhibitor of
WNK4, reducing the negative effect of WNK4 upon NCC
activity [39]. This inhibitory action on WNK4 occurs by
binding of the SGK1 protein to WNK4, which results in
SGK1-dependent phosphorylation at two sites within
WNK4, namely Ser
1169 and Ser
1196. Converting these sites
into aspartates, thereby mimicking active phosphorylation
sites, completely reverts the inhibitory effect of WNK4 on
NCC activity [39]. In an apparent feedback loop, WNK1
has been shown to activate SGK1. Interestingly, SGK1
activation is dependent on the N-terminal residues of
WNK1 and not the catalytic activity of the kinase [51,
52]. This finding has subsequently been expanded to
several of the WNKs, including WNK4 [26]. Conversely,
SGK1 has also been shown to regulate WNK1 by
phosphorylating it at Thr
58 [4]. Whether these interactions
results in altered NCC transport remains to be determined.
Since SGK1 is an aldosterone-regulated protein, under-
standing its interaction with the WNK system will help
delineate how aldosterone regulates NCC and distal
nephron NaCl transport.
Protein phosphatase 4
Regulation of NCC phosphorylation is critical in determining
its activity. As such, protein phosphatases are important for
regulating the activity of several other Slc12 family members.
ArecentreportbyGloveretal.foundthatproteinphosphatase
4 (PP4) was able to strongly inhibit NCC activity in the
Xenopus oocyte [22]. In line with previous studies, they
observed that the inhibitory actions of PP4 on NCC occur
independently of membrane trafficking. The effect of PP4
was clearly dependent on its phosphatase activity, as a
phosphatase-dead mutant had no effect upon NCC activity.
Moreover, the PP2B phosphatase had no effect on NCC
activity, suggesting specificity of PP4. Consistent with this is
the restricted expression of PP4 to the renal distal tubule.
Finally, the inhibitory effect of PP4 was only found in NCC
transporters with intact Thr
58 phosphorylation sites (Thr
60 in
humans) [22]. Thus, these data indicate an important role for
PP4 in the regulation of NCC activity, by modulating its
phosphorylation level (Fig. 4,s t e p4 ) .
γ-Adducin
The previously described studies highlight the fact that
phosphorylation of the N-terminal domain of NCC is
Pflugers Arch - Eur J Physiol (2011) 462:767–777 773critically important for cotransporter activity. Dimke et al.
utilized pull-down experiments with the N-terminal domain
of NCC as bait to screen mouse kidney lysates for potential
interactors of the cotransporter. Using this approach
coupled to mass spectrometry, γ-adducin was identified as
a novel auxiliary factor interacting with NCC [9]. The
adducin gene family was originally characterized as
cytoskeletal membrane proteins involved in spectrin–actin
binding [17]. γ-Adducin is an interesting protein based on
its proposed involvement in primary hypertension in
humans and hypertensive rat models [2, 6, 57]. Moreover,
γ-adducin co-localizes with NCC to the distal convoluted
tubule of the kidney, making it an excellent candidate
regulatory protein of NCC [9, 14]. When expressed in the
oocyte system, γ-adducin markedly stimulated the activity
of NCC. In addition, siRNA directed against the endoge-
nous X. laevis γ-adducin reduced NCC-dependent uptake,
further solidifying the role of γ-adducin in NCC regulation.
To investigate whether binding of γ-adducin to the N
terminus of NCC is required for its stimulatory effect,
competition assays were performed. Injection of increasing
amounts of the N-terminal domain into oocytes co-
expressing γ-adducin and NCC completely reverted the
stimulatory effect of γ-adducin, suggesting that binding to
the N-terminal domain is necessary to increase NCC
activity. Mapping of the γ-adducin-binding site in NCC
revealed that it bound to a segment that encompasses
several of the N-terminal phosphorylation sites. Another
clue that γ-adducin could be involved in modulating the
phosphorylation status of NCC was the observation that
cotransporter trafficking was unaltered, despite increased
activity. Mutating the phosphorylation sites in the N-
terminal domain of NCC (Thr
55, Thr
60, and Ser
73) into
aspartates, thereby mimicking constitutively active sites,
completely abolished the stimulatory effect of γ-adducin
[9]. These data indicate that phosphorylation of NCC is
integral for the stimulatory effect of γ-adducin. Moreover,
γ-adducin was found to bind NCC only in conditions when
the phosphorylation of the cotransporter was absent or low
(i.e., in the GST-purified wild-type NCC N-terminal and the
mutant N-terminal with the Thr
55, Thr
60, and Ser
73 sites
converted to alanines). However, when these phosphoryla-
tion sites were converted into aspartates, binding of γ-
adducin to NCC was abolished [9]. This suggests that γ-
adducin only binds NCC when the cotransporter is in its
dephosphorylated state.
Acknowledging that γ-adducin is not a kinase, it may
affect NCC activity by acting as a scaffold, bringing a
kinase together with its substrate NCC. As phosphory-
lation of the N-terminal sites of NCC is mediated via
SPAK and OSR1, these appear as likely candidates for
the scaffolding functions of γ-adducin. At present, pull-
down experiments with γ-adducin and the SPAK/OSR1
kinases have not been performed. Based on the initial
data obtained, a potential mechanism of how γ-adducin
binds NCC and stimulates its activity can be seen in
Fig. 4. γ- A d d u c i nm a yf u n c t i o nb yb r i n g i n gt h ek i n a s e
together with the dephosphorylated N terminus of the
cotransporter (Fig. 4, step 1). This inevitably leads to an
increase in NCC phosphorylation and subsequently activ-
ity (Fig. 4, step 2). After the kinase has phosphorylated
NCC (a feature that could lead to a conformational change
in the binding domain of the cotransporter), γ-adducin
dissociates from NCC and may even help the kinase
dissociate from the cotransporter as well (Fig. 4,s t e p3 ) .
This theory is currently speculative and remains to be
tested experimentally. Interaction studies directed at the
potential binding of γ-adducin with the STE20 kinases
will be crucial to increase our understanding of how γ-
adducin affects NCC activity.
-ADD
SPAK/
OSR1
SPAK/
OSR1
NCC
PP4 P
SPAK/
OSR1
NCC NCC
P
P
P NCC
P
Activated cotransporter
-ADD -ADD
23 4
1
Fig. 4 Schematic model detailing the postulated mechanism whereby
γ-adducin could stimulate NCC activity. This model is speculative at
current. Since γ-adducin is not a kinase, it may act as a scaffold by
anchoring a kinase (potentially SPAK or OSR1) to the dephosphory-
lated cotransporter (step 1). The anchored kinase phosphorylates
NCC, which leads to an increase in transport activity (step 2). γ-
Adducin dissociates from NCC after the kinase phosphorylates the
cotrasporter (step 3). Dephosphorylation of NCC by the PP4 protein
reduces NCC activity (step 4). The cycle can be repeated after the
cotransporter has been dephosphorylated
774 Pflugers Arch - Eur J Physiol (2011) 462:767–777The adducin gene family has previously been implicated
in arterial hypertension. Most remarkable is the role of α-
adducin. However, the effect of this isoform is likely to
occur by an alternative mechanism, as it is not expressed in
the distal tubule [14] and α-adducin does not stimulate
NCC activity in the oocyte system [9]. One single
nucleotide polymorphism in the γ-adducin gene has been
described, which is involved in systolic blood pressure
regulation in certain individuals [7]. Moreover, systolic
blood pressure and pulse rate remain stable in genetically
modified mice lacking γ-adducin. However, this is
expected since mice with a targeted deletion of NCC show
no alteration in mean arterial pressure when maintained on
normal amounts of dietary NaCl. However, when a
reduction is imposed in dietary NaCl content, NCC-
deficient mice develop hypotension [42]. Whether manip-
ulations of NaCl in the diet are needed to provoke changes
in blood pressure in γ-adducin-deficient mice remains to be
determined.
Conclusion
The kidney is a complex organ that responds to a
variety of stimuli by altering urinary excretion of
electrolytes. These adjustments depend on the signals
the kidney receives from various sources throughout the
body and from within the kidney itself. NCC plays a
key role in renal NaCl transport thereby contributing to
blood pressure maintenance. It is therefore not surpris-
ing that NCC is regulated at various levels. It is now
clear that a larger network surrounds NCC. This
network consists of kinases, scaffolds, and phosphatases
that regulate different aspects of transporter function.
Naturally, cross talk between components of this system
must occur in order to relay the most important signal
to the transporter. This integrated signaling complex
regulates NCC activity by modifying phosphorylation
status, trafficking, and lysosomal sorting. Future re-
search into this area will help explain how this complex
system regulates NCC. As such, it will be necessary to
dissect out which proteins translate the diverse array of
environmental signals into altered transporter activity. It
will also be important to establish when WNK4
stimulates or inhibits NCC activity, in order to better
understand this system.
Acknowledgments Dr. R. Todd Alexander and Dr. Catherine
Morgan are thanked for critical reading of the manuscript. Professor
René J. Bindels, Professor Joost G. Hoenderop, and Dr. Pedro San-
Cristobal are thanked for the helpful discussions on the topic. This
work was supported by the Danish Medical Research Council and an
Alberta Innovates Health Solutions Award.
Conflicts of interest The author has declared that no conflict of
interest exists.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Bergaya S, Faure S, Baudrie V, Rio M, Escoubet B, Bonnin P,
Henrion D, Loirand G, Achard JM, Jeunemaitre X, Hadchouel J
(2011) WNK1 regulates vasoconstriction and blood pressure
response to {alpha}1-adrenergic stimulation in mice. Hyperten-
sion 58:439–445
2. Bianchi G, Tripodi G, Casari G, Salardi S, Barber BR, Garcia R,
Leoni P, Torielli L, Cusi D, Ferrandi M et al (1994) Two point
mutations within the adducin genes are involved in blood pressure
variation. Proc Natl Acad Sci USA 91:3999–4003
3. Chen SY, Bhargava A, Mastroberardino L, Meijer OC, Wang J,
Buse P, Firestone GL, Verrey F, Pearce D (1999) Epithelial
sodium channel regulated by aldosterone-induced protein sgk.
Proc Natl Acad Sci USA 96:2514–2519
4. Cheng CJ, Huang CL (2011) Activation of PI3-kinase stimulates
endocytosis of ROMK via Akt1/SGK1-dependent phosphoryla-
tion of WNK1. J Am Soc Nephrol 22:460–471
5. Chiga M, Rafiqi FH, Alessi DR, Sohara E, Ohta A, Rai T, Sasaki
S, Uchida S (2011) Phenotypes of pseudohypoaldosteronism type
II caused by the WNK4 D561A missense mutation are dependent
on the WNK-OSR1/SPAK kinase cascade. J Cell Sci 124:1391–
1395
6. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M,
Glorioso N, Lanzani C, Manunta P, Righetti M, Rivera R, Stella P,
Troffa C, Zagato L, Bianchi G (1997) Polymorphisms of alpha-
adducin and salt sensitivity in patients with essential hypertension.
Lancet 349:1353–1357
7. Cwynar M, Staessen JA, Ticha M, Nawrot T, Citterio L,
Kuznetsova T, Wojciechowska W, Stolarz K, Filipovsky J,
Kawecka-Jaszcz K, Grodzicki T, Struijker-Boudier HA, Thijs L,
Van Bortel LM, Bianchi G (2005) Epistatic interaction between
alpha- and gamma-adducin influences peripheral and central pulse
pressures in white Europeans. J Hypertens 23:961–969
8. Darman RB, Forbush B (2002) A regulatory locus of phosphor-
ylation in the N terminus of the Na-K-Cl cotransporter, NKCC1. J
Biol Chem 277:37542–37550
9. Dimke H, San-Cristobal P, de Graaf M, Lenders JW, Deinum
J, Hoenderop JG, Bindels RJ (2011) gamma-Adducin
stimulates the thiazide-sensitive NaCl cotransporter. J Am
Soc Nephrol 22:508–517
10. Farfel Z, Iaina A, Rosenthal T, Waks U, Shibolet S, Gafni J (1978)
Familial hyperpotassemia and hypertension accompanied by
normal plasma aldosterone levels: possible hereditary cell mem-
brane defect. Arch Intern Med 138:1828–1832
11. Fejes-Toth G, Frindt G, Naray-Fejes-Toth A, Palmer LG (2008)
Epithelial Na+ channel activation and processing in mice lacking
SGK1. Am J Physiol Renal Physiol 294:F1298–F1305
12. Feric M, Zhao B, Hoffert JD, Pisitkun T, Knepper MA (2011)
Large-scale phosphoproteomic analysis of membrane proteins in
renal proximal and distal tubule. Am J Physiol Cell Physiol 300:
C755–C770
13. Filippi BM, de Los HP, Mehellou Y, Navratilova I, Gourlay R,
Deak M, Plater L, Toth R, Zeqiraj E, Alessi DR (2011) MO25 is a
Pflugers Arch - Eur J Physiol (2011) 462:767–777 775master regulator of SPAK/OSR1 and MST3/MST4/YSK1 protein
kinases. EMBO J 30:1730–1741
14. Fowler L, Everitt J, Stevens JL, Jaken S (1998) Redistribution and
enhanced protein kinase C-mediated phosphorylation of alpha-
and gamma-adducin during renal tumor progression. Cell Growth
Differ 9:405–413
15. Gagnon KB, England R, Delpire E (2006) Volume sensitivity of
cation-Cl− cotransporters is modulated by the interaction of two
kinases: Ste20-related proline–alanine-rich kinase and WNK4.
Am J Physiol Cell Physiol 290:C134–C142
16. Gamba G, Saltzberg SN, Lombardi M, Miyanoshita A, Lytton J,
Hediger MA, Brenner BM, Hebert SC (1993) Primary structure
and functional expression of a cDNA encoding the thiazide-
sensitive, electroneutral sodium-chloride cotransporter. Proc Natl
Acad Sci U S A 90:2749–2753
17. Gardner K, Bennett V (1987) Modulation of spectrin-actin
assembly by erythrocyte adducin. Nature 328:359–362
18. Gimenez I, Forbush B (2003) Short-term stimulation of the renal
Na-K-Cl cotransporter (NKCC2) by vasopressin involves phos-
phorylation and membrane translocation of the protein. J Biol
Chem 278:26946–26951
19. Gimenez I, Forbush B (2005) Regulatory phosphorylation sites in
the NH2 terminus of the renal Na-K-Cl cotransporter (NKCC2).
Am J Physiol Renal Physiol 289:F1341–F1345
20. Gitelman HJ, Graham JB, Welt LG (1966) A new familial
disorder characterized by hypokalemia and hypomagnesemia.
Trans Assoc Am Physicians 79:221–235
21. Glover M, Zuber AM, O'Shaughnessy KM (2009) Renal and
brain isoforms of WNK3 have opposite effects on NCCT
expression. J Am Soc Nephrol 20:1314–1322
22. Glover M, Mercier Zuber A, Figg N, O'Shaughnessy KM (2010)
The activity of the thiazide-sensitive Na(+)-Cl(-) cotransporter is
regulated by protein phosphatase PP4. Can J Physiol Pharmacol
88:986–995
23. Gonzales PA, Pisitkun T, Hoffert JD, Tchapyjnikov D, Star RA,
Kleta R, Wang NS, Knepper MA (2009) Large-scale proteomics
and phosphoproteomics of urinary exosomes. J Am Soc Nephrol
20:363–379
24. Gordon RD (1986) The syndrome of hypertension and hyper-
kalemia with normal glomerular filtration rate: Gordon’s syn-
drome. Aust N Z J Med 16:183–184
25. Hadchouel J, Soukaseum C, Busst C, Zhou XO, Baudrie V, Zurrer
T, Cambillau M, Elghozi JL, Lifton RP, Loffing J, Jeunemaitre X
(2010) Decreased ENaC expression compensates the increased
NCC activity following inactivation of the kidney-specific iso-
form of WNK1 and prevents hypertension. Proc Natl Acad Sci U
S A 107:18109–18114
26. Heise CJ, Xu BE, Deaton SL, Cha SK, Cheng CJ, Earnest S,
Sengupta S, Juang YC, Stippec S, Xu Y, Zhao Y, Huang CL,
Cobb MH (2010) Serum and glucocorticoid-induced kinase
(SGK) 1 and the epithelial sodium channel are regulated by
multiple with no lysine (WNK) family members. J Biol Chem
285:25161–25167
27. Lalioti MD, Zhang J, Volkman HM, Kahle KT, Hoffmann KE,
Toka HR, Nelson-Williams C, Ellison DH, Flavell R, Booth CJ,
Lu Y, Geller DS, Lifton RP (2006) Wnk4 controls blood pressure
and potassium homeostasis via regulation of mass and activity of
the distal convoluted tubule. Nat Genet 38:1124–1132
28. Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N,
Vallon V (2006) (Patho)physiological significance of the serum- and
glucocorticoid-inducible kinase isoforms. Physiol Rev 86:1151–
1178
29. Lin SH, Shiang JC, Huang CC, Yang SS, Hsu YJ, Cheng CJ
(2005) Phenotype and genotype analysis in Chinese patients with
Gitelman’s syndrome. J Clin Endocrinol Metab 90:2500–2507
30. Moriguchi T, Urushiyama S, Hisamoto N, Iemura S, Uchida S,
Natsume T, Matsumoto K, Shibuya H (2005) WNK1 regulates
phosphorylation of cation-chloride-coupled cotransporters via the
STE20-related kinases, SPAK and OSR1. J Biol Chem
280:42685–42693
31. Mu S, Shimosawa T, Ogura S, Wang H, Uetake Y, Kawakami-
Mori F, Marumo T, Yatomi Y, Geller DS, Tanaka H, Fujita T
(2011) Epigenetic modulation of the renal beta-adrenergic-WNK4
pathway in salt-sensitive hypertension. Nat Med 17:573–580
32. Naito S, Ohta A, Sohara E, Ohta E, Rai T, Sasaki S, Uchida S
(2010) Regulation of WNK1 kinase by extracellular potassium.
Clin Exp Nephrol 15:195–202
33. Ohta A, Rai T, Yui N, Chiga M, Yang SS, Lin SH, Sohara E,
Sasaki S, Uchida S (2009) Targeted disruption of the Wnk4 gene
decreases phosphorylation of Na-Cl cotransporter, increases Na
excretion and lowers blood pressure. Hum Mol Genet 18:3978–
3986
34. Pacheco-Alvarez D, Cristobal PS, Meade P, Moreno E, Vazquez
N, Munoz E, Diaz A, Juarez ME, Gimenez I, Gamba G (2006)
The Na+:Cl− cotransporter is activated and phosphorylated at the
amino-terminal domain upon intracellular chloride depletion. J
Biol Chem 281:28755–28763
35. Pedersen NB, Hofmeister MV, Rosenbaek LL, Nielsen J, Fenton
RA (2010) Vasopressin induces phosphorylation of the thiazide-
sensitive sodium chloride cotransporter in the distal convoluted
tubule. Kidney Int 78:160–169
36. Rafiqi FH, Zuber AM, Glover M, Richardson C, Fleming S,
Jovanovic S, Jovanovic A, O'Shaughnessy KM, Alessi DR (2010)
Role of the WNK-activated SPAK kinase in regulating blood
pressure. EMBO Mol Med 2:63–75
37. Richardson C, Rafiqi FH, Karlsson HK, Moleleki N, Vandewalle
A, Campbell DG, Morrice NA, Alessi DR (2008) Activation of
the thiazide-sensitive Na+-Cl− cotransporter by the WNK-
regulated kinases SPAK and OSR1. J Cell Sci 121:675–684
38. Rinehart J, Kahle KT, de Los HP, Vazquez N, Meade P, Wilson
FH, Hebert SC, Gimenez I, Gamba G, Lifton RP (2005) WNK3
kinase is a positive regulator of NKCC2 and NCC, renal cation-Cl
− cotransporters required for normal blood pressure homeostasis.
Proc Natl Acad Sci U S A 102:16777–16782
39. Rozansky DJ, Cornwall T, Subramanya AR, Rogers S, Yang YF,
David LL, Zhu X, Yang CL, Ellison DH (2009) Aldosterone
mediates activation of the thiazide-sensitive Na-Cl cotransporter
through an SGK1 and WNK4 signaling pathway. J Clin Invest
119:2601–2612
40. San-Cristobal P, Pacheco-Alvarez D, Richardson C, Ring AM,
Vazquez N, Rafiqi FH, Chari D, Kahle KT, Leng Q, Bobadilla
NA, Hebert SC, Alessi DR, Lifton RP, Gamba G (2009)
Angiotensin II signaling increases activity of the renal Na-Cl
cotransporter through a WNK4-SPAK-dependent pathway. Proc
Natl Acad Sci U S A 106:4384–4389
41. Sandberg MB, Riquier AD, Pihakaski-Maunsbach K, McDonough
AA, Maunsbach AB (2007) ANG II provokes acute trafficking of
distal tubule Na+-Cl(−) cotransporter to apical membrane. Am J
Physiol Renal Physiol 293:F662–F669
42. Schultheis PJ, Lorenz JN, Meneton P, Nieman ML, Riddle TM,
Flagella M, Duffy JJ, Doetschman T, Miller ML, Shull GE (1998)
Phenotype resembling Gitelman’s syndrome in mice lacking the
apical Na+-Cl− cotransporter of the distal convoluted tubule. J
Biol Chem 273:29150–29155
43. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE,
Molina AM, Vaara I, Iwata F, Cushner HM, Koolen M, Gainza FJ,
Gitleman HJ, Lifton RP (1996) Gitelman’s variant of Bartter’s
syndrome, inherited hypokalaemic alkalosis, is caused by muta-
tions in the thiazide-sensitive Na-Cl cotransporter. Nat Genet
12:24–30
776 Pflugers Arch - Eur J Physiol (2011) 462:767–77744. Subramanya AR, Liu J, Ellison DH, Wade JB, Welling PA (2009)
WNK4 diverts the thiazide-sensitive NaCl cotransporter to the
lysosome and stimulates AP-3 interaction. J Biol Chem
284:18471–18480
45. Vallon V, Schroth J, Lang F, Kuhl D, Uchida S (2009) Expression
and phosphorylation of the Na+-Cl− cotransporter NCC in vivo is
regulated by dietary salt, potassium, and SGK1. Am J Physiol
Renal Physiol 297:F704–F712
46. Verissimo F, Jordan P (2001) WNK kinases, a novel protein kinase
subfamily in multi-cellular organisms. Oncogene 20:5562–5569
47. Vitari AC, Deak M, Morrice NA, Alessi DR (2005) The WNK1
a n dW N K 4p r o t e i nk i n a s e st h a ta r em u t a t e di nG o r d o n ’s
hypertension syndrome phosphorylate and activate SPAK and
OSR1 protein kinases. Biochem J 391:17–24
48. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K,
Nelson-Williams C, Desitter I, Gunel M, Milford DV, Lipkin
GW, Achard JM, Feely MP, Dussol B, Berland Y, Unwin RJ,
Mayan H, Simon DB, Farfel Z, Jeunemaitre X, Lifton RP
(2001) Human hypertension caused by mutations in WNK
kinases. Science 293:1107–1112
49. Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover
RS, Hebert SC, Gamba G, Lifton RP (2003) Molecular patho-
genesis of inherited hypertension with hyperkalemia: the Na-Cl
cotransporter is inhibited by wild-type but not mutant WNK4.
Proc Natl Acad Sci USA 100:680–684
50. Xu B, English JM, Wilsbacher JL, Stippec S, Goldsmith EJ, Cobb
MH (2000) WNK1, a novel mammalian serine/threonine protein
kinase lacking the catalytic lysine in subdomain II. J Biol Chem
275:16795–16801
51. Xu BE, Stippec S, Chu PY, Lazrak A, Li XJ, Lee BH, English JM,
Ortega B, Huang CL, Cobb MH (2005) WNK1 activates SGK1 to
regulate the epithelial sodium channel. Proc Natl Acad Sci U S A
102:10315–10320
52. Xu BE, Stippec S, Lazrak A, Huang CL, Cobb MH (2005) WNK1
activates SGK1 by a phosphatidylinositol 3-kinase-dependent and
non-catalytic mechanism. J Biol Chem 280:34218–34223
53. Yang CL, Angell J, Mitchell R, Ellison DH (2003) WNK kinases
regulate thiazide-sensitive Na-Cl cotransport. J Clin Invest
111:1039–1045
54. Yang SS, Morimoto T, Rai T, Chiga M, Sohara E, Ohno M,
Uchida K, Lin SH, Moriguchi T, Shibuya H, Kondo Y, Sasaki S,
Uchida S (2007) Molecular pathogenesis of pseudohypoaldoster-
onism type II: generation and analysis of a Wnk4(D561A/+)
knockin mouse model. Cell Metab 5:331–344
55. Yang CL, Zhu X, Ellison DH (2007) The thiazide-sensitive Na-Cl
cotransporter is regulated by a WNK kinase signaling complex. J
Clin Invest 117:3403–3411
56. Yang SS, Lo YF, Wu CC, Lin SW, Yeh CJ, Chu P, Sytwu HK,
Uchida S, Sasaki S, Lin SH (2010) SPAK-knockout mice manifest
Gitelman syndrome and impaired vasoconstriction. J Am Soc
Nephrol 21:1868–1877
57. Zagato L, Modica R, Florio M, Torielli L, Bihoreau MT, Bianchi G,
Tripodi G (2000) Genetic mapping of blood pressure quantitative
trait loci in Milan hypertensive rats. Hypertension 36:734–739
58. Zambrowicz BP, Abuin A, Ramirez-Solis R, Richter LJ, Piggott J,
BeltrandelRio H, Buxton EC, Edwards J, Finch RA, Friddle CJ,
Gupta A, Hansen G, Hu Y, Huang W, Jaing C, Key BW Jr, Kipp
P, Kohlhauff B, Ma ZQ, Markesich D, Payne R, Potter DG, Qian
N, Shaw J, Schrick J, Shi ZZ, Sparks MJ, Van Sligtenhorst I,
Vogel P, Walke W, Xu N, Zhu Q, Person C, Sands AT (2003)
Wnk1 kinase deficiency lowers blood pressure in mice: a gene-
trap screen to identify potential targets for therapeutic interven-
tion. Proc Natl Acad Sci U S A 100:14109–14114
59. Zhou B, Zhuang J, Gu D, Wang H, Cebotaru L, Guggino WB, Cai
H (2009) WNK4 enhances the degradation of NCC through a
sortilin-mediated lysosomal pathway. J Am Soc Nephrol 21:82–92
Pflugers Arch - Eur J Physiol (2011) 462:767–777 777